<DOC>
	<DOCNO>NCT02251600</DOCNO>
	<brief_summary>Study characterize single-state steady-state dose oral deflazacort pediatric adolescent subject .</brief_summary>
	<brief_title>A Pharmacokinetic Study Oral Deflazacort Children Adolescent Subjects With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Deflazacort</mesh_term>
	<criteria>In opinion investigator , subject capable understanding comply protocol requirement . The subject , applicable , subject 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . If age 7 , subject sign date write , informed assent form ( IAF ) require privacy authorization prior initiation study procedure . The subject must confirm diagnosis Duchenne Muscular Dystrophy define muscle biopsy dystrophin analyse consistent DMD DNA mutation analysis PCR Southern blot technique detect gene deletion well : 1. onset weakness 5 year age ; 2. proximal muscle weakness ; 3. increase serum creatine kinase 10 time upper limit normal ( ULN ) ; The subject male age 4 16 year , inclusive . The subject weigh least 13 kg Body Mass Index ( BMI ) ≤ 40 . Willingness ability comply schedule visit , oral drug administration , study procedure include blood sample draw ( total blood volume collect exceed 50 mL study duration 25 mL single study day [ ≤ 3 mL/kg ] ) The subject life expectancy &gt; 1 year . Up date childhood vaccination , specifically varicella vaccine ( chicken pox ) . Baseline health judge stable base medical history , physical examination , laboratory profile , vital sign , ECGs screening , deem Investigator . Continuous non smoker use nicotine containing product least 3 month prior first dose . The subject able take tablet . The subject receive investigational compound and/or participate another clinical study within 90 day prior study treatment exception observational cohort study noninterventional study . The subject receive deflazacort within 30 day previous discontinued deflazacort due intolerable reaction . The subject immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g . spouse , parent , child , sibling ) may consent duress . Any significant finding Columbia suicide severity rating scale ( C SSRS ) subject ( age 1216 , inclusive ) , opinion PI , warrant exclusion study . The subject , judgment investigator , clinically significant abnormal clinical chemistry laboratory parameter may affect safety Screening . The subject , judgment investigator , history current medical condition could affect safety include , limited : 1 . Major renal hepatic impairment 2 . Immunosuppression contraindication corticosteroid treatment 3 . History chronic systemic fungal viral infection 4 . Diabetes mellitus 5 . Idiopathic hypocalcuria 6 . Symptomatic cardiomyopathy screen The subject history hypersensitivity allergic reaction steroid formulation include , limited lactose , sucrose , etc . Inability take tablet assess site investigator . Unable refrain anticipates use : Any medication least 4 hour dose PK Days 1 8 . Any vitamin , vitamin mineral , and/or meal supplementation ( e.g. , Ensure , Boost , etc . ) least 4 hour dose PK Days 1 8 . Any drug , include prescription non prescription medication , herbal remedy know significant inhibitor CYP 3A4 enzyme and/or P gp 14 day prior first dose study drug throughout study . Appropriate source consult PI designee confirm lack pharmacokinetic/pharmacodynamic interaction study drug . Acetaminophen may permit study ( dos base upon appropriate age/weight range . Any drug know significant inducer CYP 3A4 enzyme and/or P gp 28 day prior first dose study drug throughout study . Appropriate source consult PI designee confirm lack PK/pharmacodynamics interaction study drug . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . History illness , opinion PI , might confound result study pose additional risk subject participation study . Positive urine drug alcohol result screen check . Positive urine cotinine screening . Positive result screen HIV , HBsAg , HCV . Hemoglobin level lower limit normal screening . Donation blood significant blood loss within 56 day prior first dose study drug .</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Deflazacort</keyword>
</DOC>